Home › Compare › OJSCY vs ABBV
OJSCY yields 68.19% · ABBV yields 3.06%● Live data
📍 OJSCY pulled ahead of the other in Year 1
Combined, OJSCY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of OJSCY + ABBV for your $10,000?
Public Joint Stock Company Rosneft Oil Company, together with its subsidiaries, engages in the exploration, development, production, and sale of crude oil and gas. It operates in two segments, Exploration and Production; and Refining and Distribution. The company produces liquid hydrocarbons in Western and Eastern Siberia, Timan-Pechora, Ural-Volga, Southern part of European Russia, and the Russian Far East. It is also involved in producing petrochemicals products; base and industrial oils; motor and transmission oils for cars and trucks, buses, agricultural and special equipment, and railway and marine transport; special oils for the aviation industry; hydraulic, gear, turbine, compressor, transformer oils, etc.; coolants, softener oils, paraffins, etc.; and additives to fuels and oils. In addition, the company transports and exports crude oil through pipelines, and railway and mixed transportation; sells petrochemicals and liquefied petroleum gas, which include phenolic chain, aromatics, polymers, olefins, alcohols, oil refinement, fuel material, and other petrochemical products; and provides bunkering and aircraft refueling services, as well as bitumen products. Further, it operates a network of filling stations. The company was founded in 1995 and is based in Moscow, Russia. Public Joint Stock Company Rosneft Oil Company operates as a subsidiary of OJSC Rosneftegaz.
Full OJSCY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.